October Pharma SAE (OCPH)

Cairo – Mubasher: The board of October Pharma approved the estimated budget for 2022, expecting a net profit after tax worth EGP 135 million by the end of the year. The company also targets sales worth EGP 775 million this year, according to a …

Cairo – Mubasher: October Pharma achieved a 65% year-on-year (YoY) increase in its net profits, logging EGP 100.32 million in the first nine months of 2021, compared to EGP 60.67 million.  The revenues levelled up to EGP 489.07 million in the …

Cairo – Mubasher: October Pharma recorded a surge of 402% in net profits to EGP 40.59 million during the first quarter (Q1) of 2021, compared to EGP 8.08 million in the same quarter a year ago. Revenues increased by 38% to total EGP 165.83 million …

Cairo – Mubasher: The ordinary general meeting (OGM) of October Pharma approved a cash dividend of 30% of the capital or EGP 3 per share for 2020. The shareholders also decided to postpone the issuance of bonus shares for further consideration, …

Cairo – Mubasher: October Pharma’s net profits for the year 2020 leapt by 161% on an annual basis, driven by lower production costs and expenses, to reach EGP 88.26 million. Revenue hiked to EGP 543 million last year from EGP 523 million a year …

Cairo – Mubasher: The board of October Pharma has approved the estimated budget for fiscal year (FY) 2021. The budget aims to achieve sales of EGP 655 million and after-tax net profits of EGP 91.4 million, according to a stock exchange statement …

Cairo – Mubasher: October Pharma reported a 227.5% year-on-year (YoY) leap in its net profits, registering EGP 60.6 million in the first nine months of 2020, compared to EGP 18.5 million. Revenues grew to EGP 379 million in the January-September …

Cairo – Mubasher: The net profits of October Pharma hiked by 711% year-on-year (YoY) to EGP 27 million in the first half (H1) of 2020, compared to EGP 3.33 million. The company’s revenues rose to EGP 244 million in the six-month period ended on 30 …

Cairo – Mubasher: October Pharma said that its ordinary general meeting (OGM) approved the board’s proposal for cash dividends for the year ended 31 December 2019. The company’s shareholders agreed to distribute EGP 1.5 per share or 15% of the …

Cairo – Mubasher: October Pharma reported an 84.6% year-on-year surge in its net profits during 2019 on the back of higher sales. The pharmaceutical company’s net profits hiked to EGP 33.83 million last year from EGP 18.3 million in the previous …

Cairo – Mubasher: October Pharma reported an 80% year-on-year profit surge during 2019 on the back of higher sales, according to the company’s financial indicators. Net profits soared to EGP 32.5 million last year from EGP 18 million in 2018, the …

Cairo – Mubasher: The unaudited financial results of October Pharma reported an 18.75% year-on-year increase in its profits during the first nine months of 2019. Net profits amounted to EGP 19 million during the January-September period, compared …

Cairo – Mubasher: The board of directors of October Pharma assented to increase the firm’s capital by EGP 60 million. The company’s issued, paid-up, and authorised capital will be increased to EGP 120 million from EGP 60 million, the company said …

Cairo – Mubasher: The board of directors of October Pharma approved to close the firm’s unit in the UAE. The board’s decision followed a change in circumstances on which the said branch was established, according to a disclosure to the Egyptian …

Cairo- Mubasher: The financial statements of October Pharma indicated a 66.6% year-on-year decline in profits during the first half of 2019. Year-on-year, the profits plunged to EGP 3.33 million in H1-19, when compared to EGP 9.99 million, …

Cairo – Mubasher: October Pharma on Monday announced that its shareholders had approved the board of directors’ proposal to distribute a cash dividend of EGP 1 per share for 2018 during an ordinary general meeting (OGM), according to the firm’s …

Cairo – Mubasher: October Pharma’s ordinary general meeting (OGM) will convene on Sunday to discuss the company’s dividend distributions among other items. October Pharma’s board had recommended a cash dividend totalling EGP 24 million, …

Cairo – Mubasher: October Pharma on Monday reported a 60% year-on-year rise in profits for 2017 due to a growth in revenues. Net profit stood at EGP 56 million last year, up from EGP 35 million in 2016, the company said in a filing to the Egyptian …

Cairo – Mubasher: October Pharma aims at raising its sales by 31% to EGP 480 million in 2018 as part of the company’s budget plan. The target increase in sales does not include Sigma Co’s cosmetics, which made up 10% of the company's last …

Cairo – Mubasher: Egypt’s Ministry of Health has assigned four companies to locally produce penicillin, a ministry spokesperson has said. The companies that will be in charge of the local production of the drug are: Nile Pharmaceuticals and …

Cairo – Mubasher: October Pharma’s said Thursday that it will pay coupon no. 9 at EGP 3.5 per share to shareholders of record until 8 May. The coupon will be distributed starting 11 May, according to a bourse filing.

Cairo – Mubasher: The ordinary general meeting (OGM) of October Pharma has approved to increase cash dividends for fiscal year 2016 to EGP 3.5 from proposed dividends of EGP 3. The OGM also adopted the financial statements for the year ended on 31 …

Cairo - Mubasher: The financial indicators of October Pharma have shown a growth in annual profits by 118.8% last year, with a recommendation of distributing cash dividends to shareholders at 30% of the capital. The company’s profits totalled EGP …

Cairo – Mubasher: The Egyptian Exchange announced Tuesday that the span set for buying 7.89% of October Pharma will expire today, according to a bourse statement. Earlier, the bourse opened the OPR market for three days (22-24 January) to sell a …

Cairo – Mubahser: October Pharma said it expects to incur losses of EGP 50 million in 2017, amid the continuous increase in the production cost. The drug firm studies suspending the production of 30 medicines due to the sharp devaluation of the …